T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants
出版年份 2019 全文链接
标题
T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2019-03-28
DOI
10.1093/annonc/mdz112
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis
- (2018) Peter Savas et al. NATURE MEDICINE
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictors of responses to immune checkpoint blockade in advanced melanoma
- (2017) N. Jacquelot et al. Nature Communications
- Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition
- (2017) Carlos R. Gil Del Alcazar et al. Cancer Discovery
- A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
- (2016) M. Bacac et al. CLINICAL CANCER RESEARCH
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- The use of CrossMAb technology for the generation of bi- and multispecific antibodies
- (2016) Christian Klein et al. mAbs
- Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling
- (2016) Hee Jin Lee et al. Oncotarget
- CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors
- (2016) Marina Bacac et al. OncoImmunology
- The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ
- (2016) Michaela Semeraro et al. OncoImmunology
- rCGH: a comprehensive array-based genomic profile platform for precision medicine
- (2015) Frederic Commo et al. BIOINFORMATICS
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Natural and therapy-induced immunosurveillance in breast cancer
- (2015) Guido Kroemer et al. NATURE MEDICINE
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data
- (2014) Svasti Haricharan et al. BREAST CANCER RESEARCH AND TREATMENT
- Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
- (2014) Fabrice André et al. LANCET ONCOLOGY
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- CD3 -Chain Expression of Human T Lymphocytes Is Regulated by TNF via Src-like Adaptor Protein-Dependent Proteasomal Degradation
- (2012) B. Ersek et al. JOURNAL OF IMMUNOLOGY
- Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression
- (2012) Masayuki Inoue et al. OncoImmunology
- Clinical implication of HLA class I expression in breast cancer
- (2011) Koichi Kaneko et al. BMC CANCER
- Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer
- (2011) D. Miles et al. ONCOLOGIST
- T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2
- (2010) Kousaku Mimura et al. INTERNATIONAL JOURNAL OF CANCER
- Bispecific T-Cell Engaging Antibodies for Cancer Therapy
- (2009) P. A. Baeuerle et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started